BLUE BELL, Pa.--(BUSINESS WIRE)--Impact Education, LLC, announced today the release of a new white paper based on key findings from the Therapeutic CGM Health Care Stakeholder Summit held on Nov. 7, 2019, in Washington, DC. The stakeholder panel included payer and employer leadership along with clinical experts in the field of endocrinology. The purpose was to gather input pertinent to the coverage and application of therapeutic continuous glucose monitoring (CGM) in managed care settings. Evidence supporting the clinical and economic value of real-time CGM (rtCGM) was presented and the insights of these health care stakeholders were captured to formulate coverage policy recommendations for the future. This input is intended to advance the uptake and appropriate coverage of evidence-based health technology interventions by managed care organizations (MCOs) and various payers.
The white paper is hosted on www.ManagedCareCGM.com, the new premier source for the latest news, resources and continuing education on CGM. ManagedCareCGM.com is designed specifically for the educational needs of managed care, pharmacy and payer professionals. The website features expert interviews on best practices from leading managed care and specialty pharmacy professionals as well as real-world accredited case studies presented by key managed care decision makers. To view or download a copy of the white paper, please visit www.ManagedCareCGM.com. The website and white paper are supported by an educational grant from DexCom, Inc.
About Impact Education, LLC
Impact Education, LLC (IMPACT), is an award-winning medical education and communications company dedicated to providing high quality educational programs. IMPACT’s mission is to develop education that improves patient outcomes in combination with increased health care efficiency and cost-effectiveness. The majority of activities developed by IMPACT are focused on the needs of the managed care and payer audiences. For more information, visit www.impactedu.net and follow us on Facebook and Twitter.
